Marché mondial de la maladie de Gaucher – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché                              

La maladie de Gaucher est une maladie métabolique héréditaire dans laquelle le glucocérébroside, une forme de graisse (lipide), est incapable de se décomposer. La glucocérébrosidase est une enzyme qui décompose et retraite le glucocérébroside dans le corps humain. La maladie de Gaucher est causée par des mutations du gène GBA, qui entraînent de très faibles niveaux de l'enzyme glucocérébrosidase, ce qui ralentit la dégradation du glucocérébroside. La maladie de Gaucher est caractérisée par l'un des trois types suivants : type 1, type 2 ou type 3. La maladie de Gaucher est classée en type 1, type 2 et type 3. Le type 1 est le plus fréquent, tandis que les types 2 et 3 sont moins courants.

Français Data Bridge Market Research analyse que le marché de la maladie de Gaucher était évalué à 1,54 milliard USD en 2021 et devrait atteindre 1,88 milliard USD d'ici 2029, enregistrant un TCAC de 2,50 % au cours de la période de prévision de 2022 à 2029. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

Gaucher disease is caused by an accumulation of fatty substances in your organs, especially your spleen and liver. These organs increase as a result of this, which can have an impact on their function. While Gaucher disease has no cure, there are a number of treatments that can help manage symptoms, avoid irreparable damage, and enhance quality of life. The defective enzyme is replaced with artificial enzymes in enzyme replacement therapy. Iglucerase, velaglucerase alfa and taliglucerase are the three ERT medicines currently approved by the FDA (Elelyso). Transfusions of blood products for severe anaemia and bleeding; analgesics for bone pain; joint replacement surgery for chronic pain alleviation and function restoration; and anti-bone resorption medicines, calcium, and vitamin D for osteoporosis

Gaucher Disease Market Dynamics

Drivers

• Rising prevalence of lysosomal disease

The rising prevalence of lysosomal disease will act as a major driver that will result in the expansion of the market's growth rate. Lysosomal storage disorders are inherited metabolic disorders marked by an abnormal accumulation of numerous harmful chemicals in the body's cells as a result of enzyme shortages. For those with Gaucher disease type I, enzyme replacement therapy (ERT) has been shown to be successful. Anemia and low platelet counts have improved, liver and spleen enlargement has decreased significantly, and skeletal abnormalities have improved. Individuals with Gaucher disease types II and III who get ERT also see improvements in these systemic signs.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of Gaucher disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, surging number of government initiatives to spread awareness and rising adoption rate of early diagnosis will result in the expansion of Gaucher disease market. Along with this, rising level of disposable income and increasing the need for better disease treatment options will enhance the market's growth rate.

Opportunities

• Rise in RandD activities  

The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the Gaucher disease market growth. For instance, biodistribution studies in LSD models provide evidence for the theory that the RTB-lectin transports corrective doses of enzymes across the blood–brain barrier for the treatment of central nervous system pathologies, according to researchers from BioStrategies LC, State University (U.S.).

Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the Gaucher disease market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of Gaucher disease market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the Gaucher disease market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This Gaucher disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Gaucher disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Gaucher disease is a recessive gene dominant disease that has a wide range of clinical manifestations. It is the most prevalent lysosomal storage disorder, with a prevalence of 1 in every 50,000 live births. The fatal perinatal type of the disease is the most severe. Gaucher disease is thought to manifest itself most strongly in the Jewish population of Eastern and Central Europe, affecting one out of every 450 persons and resulting in one out of every ten disease carriers within the descend.

Gaucher disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

Global Gaucher Disease Market Scope

The Gaucher disease market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Physical Exam
• Blood Tests
• Imaging Tests
• Preconception Screening and Prenatal Testing
• Others

Type

• Gaucher Disease Type 1
• Gaucher Disease Type 2
• Gaucher Disease Type 3
• Others

Treatment

• Surgery
• Spleen removal
• Bone-marrow transplant
• Others
• Medication
• Enzyme replacement therapy
• Iglucerase
• Velaglucerase alfa
• Taliglucerase
• Osteoporosis drugs
• Glucosylceramide synthase inhibitors
• Others
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Gaucher Disease Market Regional Analysis/Insights

The Gaucher disease market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Gaucher disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Gaucher disease market because of the rising healthcare expenditure and highly sophisticated medical facilities in this region. Additionally, growing focus of major key players in research and development activities for Gaucher disease will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow significantly during the forecast period of 2022-2029 due to presence of key market players in this region. Also, the development of healthcare infrastructure and high diagnostic rate will further propel the market's growth rate in this region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché de la maladie de Gaucher

Le paysage concurrentiel du marché de la maladie de Gaucher fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la maladie de Gaucher.

Certains des principaux acteurs opérant sur le marché de la maladie de Gaucher sont :

• Novartis SA (Suisse)
• Johnson and Johnson Private Limited (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Irlande)
• Merck and Co., Inc. (États-Unis)
• Allergan (Irlande)
• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Sanofi (France)
• Merck KGaA (Allemagne)
• Abbott (États-Unis)
• Boehringer Ingelheim International GmbH. (Allemagne)
• Takeda Pharmaceutical Company Limited (Japon)
• Amicus Therapeutics, Inc. (États-Unis)
• Moderna, Inc. (États-Unis)
• Greenovation Biotech GmbH (Allemagne)
• Biomarin (États-Unis)
• JCR Pharmaceuticals Co., Ltd (Japon)
• ISU ABXIS (Corée du Sud)
• Idorsia Pharmaceuticals SA (Suisse)
• AVROBIO, Inc. (États-Unis)
• Resverlogix Corp. (Canada)
• Enzyvant (États-Unis)
• CHIESI Farmaceutici SpA (Italie)

SKU-53449